Back to Search
DOUGLAS MCNEEL, MD PHD
MD PHD
Medical Oncology Physician
NPI: 1104892280IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
43354(WI)
Education
UNIVERSITY OF CHICAGO, PRITZKER SCHOOL OF MEDICINE
Class of 1994
Research & Publications (20)
Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer.
PMID 19636017·J Clin Oncol·2009
3-trial
Prostate cancer antigens and vaccines, preclinical developments.
PMID 16110615·Cancer Chemother Biol Response Modif·2005
6-review
Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion.
PMID 16278408·Clin Cancer Res·2005
3-trial
Pilot study of an HLA-A2 peptide vaccine using flt3 ligand as a systemic vaccine adjuvant.
PMID 12645861·J Clin Immunol·2003
3-trial
An aberrant prostate antigen-specific immune response causes prostatitis in mice and is associated with chronic prostatitis in humans.
PMID 19603556·J Clin Invest·2009
7-preclinical
Methods for constructing and evaluating antitumor DNA vaccines.
PMID 19565905·Methods Mol Biol·2009
7-preclinical
Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen.
PMID 19401350·Clin Cancer Res·2009
8-other
Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF.
PMID 19147575·Cancer Res·2009
3-trial
His-tag ELISA for the detection of humoral tumor-specific immunity.
PMID 18510754·BMC Immunol·2008
4-observational
A phase I pharmacokinetic and pharmacodynamic correlative study of the antisense Bcl-2 oligonucleotide g3139, in combination with carboplatin and paclitaxel, in patients with advanced solid tumors.
PMID 18451239·Clin Cancer Res·2008
3-trial
Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer.
PMID 18413835·Clin Cancer Res·2008
3-trial
Immunotherapy for prostate cancer - recent progress in clinical trials.
PMID 17679921·Clin Adv Hematol Oncol·2007
6-review
Effects of a monoclonal anti-alphavbeta3 integrin antibody on blood vessels - a pharmacodynamic study.
PMID 17001523·Invest New Drugs·2007
3-trial
Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cells.
PMID 17102977·Cancer Immunol Immunother·2007
7-preclinical
Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy.
PMID 17308272·J Clin Oncol·2007
3-trial
Antibody and T-cell responses specific for the androgen receptor in patients with prostate cancer.
PMID 17879963·Prostate·2007
8-other
MAD-CT-2 identified as a novel melanoma cancer-testis antigen using phage immunoblot analysis.
PMID 17893560·J Immunother·2007
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 600 HIGHLAND AVE
MADISON, WI 53792 - Phone
- (608) 265-1700
Quick Facts
- NPI
- 1104892280
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 32
- Publications
- 20
Are you this provider?
Claim Your Profile